Patents by Inventor Sami Oikarinen
Sami Oikarinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911456Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: April 7, 2021Date of Patent: February 27, 2024Assignee: Vactech OyInventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 11786564Abstract: The invention discloses an immunomodulatory composition comprising non-culturable bacteria, a method of production and an article and an apparatus for its use and administration.Type: GrantFiled: April 6, 2022Date of Patent: October 17, 2023Assignee: Uute Scientific OyInventors: Aki Sinkkonen, Mira Grönroos, Heikki Hyöty, Olli-Heikki Laitinen, Noora Nurminen, Sami Oikarinen
-
Patent number: 11633468Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: August 17, 2020Date of Patent: April 25, 2023Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20220354906Abstract: The invention discloses an immunomodulatory composition comprising non-culturable bacteria, a method of production and an article and an apparatus for its use and administration.Type: ApplicationFiled: April 6, 2022Publication date: November 10, 2022Inventors: Aki Sinkkonen, Mira Grõnroos, Heikki Hyöty, Olli-Heikki Laitinen, Noora Nurminen, Sami Oikarinen
-
Patent number: 11318173Abstract: The invention discloses an immunomodulatory composition comprising non-culturable bacteria, a method of production and an article and an apparatus for its use and administration.Type: GrantFiled: December 7, 2017Date of Patent: May 3, 2022Assignee: Uute Scientific OyInventors: Aki Sinkkonen, Mira Grönroos, Heikki Hyöty, Olli-Heikki Laitinen, Noora Nurminen, Sami Oikarinen
-
Publication number: 20210220465Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: April 7, 2021Publication date: July 22, 2021Inventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20210023196Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: August 17, 2020Publication date: January 28, 2021Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10780157Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: February 1, 2019Date of Patent: September 22, 2020Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10675344Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: February 1, 2019Date of Patent: June 9, 2020Assignee: Vactech 0yInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20200000908Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: February 1, 2019Publication date: January 2, 2020Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20190343898Abstract: The invention discloses an immunomodulatory composition comprising non-culturable bacteria, a method of production and an article and an apparatus for its use and administration.Type: ApplicationFiled: December 7, 2017Publication date: November 14, 2019Inventors: Aki Sinkkonen, Mira Grönroos, Heikki Hyöty, Olli-Heikki Laitinen, Noora Nurminen, Sami Oikarinen
-
Publication number: 20190209675Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: February 1, 2019Publication date: July 11, 2019Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10258685Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: March 22, 2017Date of Patent: April 16, 2019Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20170281748Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: March 22, 2017Publication date: October 5, 2017Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20140255425Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Inventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20130101992Abstract: There is an association between enteroviruses and type 1 diabetes (T1D). The present invention is based on the finding that particular enterovirus serotypes are T1D risk serotypes, while others are protective against the disease. The present invention relates to a diagnostic assay for type 1 diabetes (T1D), and especially to an assay for predicting the risk of contracting the disease. It also relates to a method of monitoring the efficacy of antiviral treatments aiming at prevention of T1D. The invention still further relates to a diagnostic kit.Type: ApplicationFiled: June 30, 2011Publication date: April 25, 2013Applicant: Vactech OYInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20120003240Abstract: Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond, Malin Flodstrom-Tullberg
-
Publication number: 20120003239Abstract: New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20120003238Abstract: Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20110002943Abstract: The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease.Type: ApplicationFiled: November 28, 2008Publication date: January 6, 2011Inventors: Heikki Hyöty, Sisko Tauriainen, Sami Oikarinen, Maarit Oikarinen, Markku Mäki, Katri Kaukinen, Teemu Honkanen, Immo Rantala